MCID: ESP021
MIFTS: 79

Esophageal Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Skin diseases, Gastrointestinal diseases

Aliases & Classifications for Esophageal Cancer

MalaCards integrated aliases for Esophageal Cancer:

Name: Esophageal Cancer 53 37 12 49 71 36 13 40 14
Esophageal Carcinoma 12 51 14 69
Esophageal Squamous Cell Carcinoma 53 55 71
Squamous Cell Carcinoma of Esophagus 55 69
Gastric Cardia Adenocarcinoma 71 69
Carcinoma of Esophagus 12 28
Esophageal Neoplasms 41 69
Esophageal Neoplasm 72 28
Esophagus Cancer 12 49
Escc 55 71
Malignant Tumor of the Middle Third of the Esophagus 12
Malignant Neoplasm of Proximal Third of Esophagus 12
Malignant Neoplasm of Middle Third of Oesophagus 12
Malignant Neoplasm of Distal Third of Esophagus 12
Malignant Neoplasm of Lower Third of Oesophagus 12
Malignant Neoplasm of Middle Third of Esophagus 69
Malignant Tumor of Proximal Third of Esophagus 12
Malignant Tumor of Distal Third of Esophagus 12
Esophageal Squamous Cell Carcinoma, Somatic 53
Malignant Neoplasm of Upper Third Esophagus 12
Malignant Tumor of Abdominal Esophagus 12
Esophageal Epidermoid Carcinoma 55
Squamous Cell Esophageal Cancer 51
Malignant Neoplasm of Esophagus 69
Esophageal Carcinoma, Somatic 53
Esophageal Cancer, Somatic 53
Ca Middle Third Oesophagus 12
Aerodigestive Tract Cancer 71
Ca Lower Third Oesophagus 12
Carcinoma of Oesophagus 12
Cancer of Oesophagus 12
Cancer of Esophagus 12
Escr 71

Characteristics:

Orphanet epidemiological data:

55
squamous cell carcinoma of esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (Worldwide); Age of onset: Adult; Age of death: adult;

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
esophageal cancer:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Esophageal Cancer

OMIM : 53 Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most common cancers worldwide. Both environmental and genetic risk factors play a role in the pathogenesis of the disorder. In Europe and North America, heavy smoking, alcohol consumption, and increased body mass index (BMI) are the main environmental risk factors. In contrast, the particularly high incidence of ESCC in some areas of China, central Asia, and southern Africa is associated with nutritional deficiencies, high intake of nitrosamine-rich or pickled vegetables, and low socioeconomic status; smoking, alcohol consumption, and BMI play a lesser role in these populations. There is a tendency for familial aggregation of ESCC in high-risk geographic areas, suggesting a genetic component to increased susceptibility. Gastric cardia adenocarcinoma is another common type of cancer in China that shows similarities to ESCC in terms of geographic distribution and environmental risk factors (summary by Wang et al., 2010 and Abnet et al., 2010). (133239)

MalaCards based summary : Esophageal Cancer, also known as esophageal carcinoma, is related to gastric cardia adenocarcinoma and mucoepidermoid esophageal carcinoma, and has symptoms including chest pain, abnormality of the voice and cough. An important gene associated with Esophageal Cancer is TGFBR2 (Transforming Growth Factor Beta Receptor 2), and among its related pathways/superpathways are MicroRNAs in cancer and Endometrial cancer. The drugs Photodynamic Therapy (& Photofrin) and Photofrin have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and testes, and related phenotypes are immune system and endocrine/exocrine gland

UniProtKB/Swiss-Prot : 71 Esophageal cancer: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage.

NIH Rare Diseases : 49 Esophageal cancer is a cancer of the esophagus, the hollow tube that carries food and liquids from the throat to the stomach. As the cancer grows, symptoms may include painful or difficult swallowing, weight loss and coughing up blood. The exact cause is usually not known, but both environmental and genetic factors are throught to play a role in the development of this condition. In the United States, risk factors for developing esophageal cancer include smoking, heavy drinking, obesity, and damage from acid reflux. Treatments include surgery, radiation, chemotherapy, and laser therapy. Some patients may also need nutritional support, since the cancer or treatment may make it hard to swallow. Last updated: 1/12/2012

MedlinePlus : 40 The esophagus is a hollow tube that carries food and liquids from your throat to your stomach. Early esophageal cancer usually does not cause symptoms. Later, you may have symptoms such as Painful or difficult swallowing Weight loss A hoarse voice or cough that doesn't go away You're at greater risk for getting esophageal cancer if you smoke, drink heavily, or have acid reflux. Your risk also goes up as you age Your doctor uses imaging tests and a biopsy to diagnose esophageal cancer. Treatments include surgery, radiation, and chemotherapy. You might also need nutritional support, since the cancer or treatment may make it hard to swallow. NIH: National Cancer Institute

Disease Ontology : 12 A gastrointestinal system cancer that is located in the esophagus.

Wikipedia : 72 Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and... more...

Related Diseases for Esophageal Cancer

Diseases related to Esophageal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
# Related Disease Score Top Affiliating Genes
1 gastric cardia adenocarcinoma 35.0 TGFBR2 TP53 WWOX
2 mucoepidermoid esophageal carcinoma 34.2 TP53 WWOX
3 adenocarcinoma 32.3 CCND1 CDKN2A HRAS TGFBR2 TP53
4 mutagen sensitivity 31.5 CCND1 GSTM1 TP53
5 oral leukoplakia 31.0 CDKN2A GSTM1 TP53
6 barrett esophagus 30.9 CCND1 CDKN2A FHIT TP53
7 retinoblastoma 30.9 CCND1 CDK4 CDKN2A TP53
8 esophagus adenocarcinoma 30.7 CDKN2A TP53 WWOX
9 tongue cancer 30.7 CCND1 CDKN2A TP53 VEGFC
10 squamous cell carcinoma 30.5 CCND1 CDKN2A DLEC1 FHIT HRAS RNF6
11 gastric cancer 30.2 CCND1 CDKN2A FHIT GSTM1 HRAS TGFBR2
12 oral squamous cell carcinoma 30.0 CCND1 CDKN2A HRAS TP53 VEGFC
13 hepatocellular carcinoma 29.9 CCND1 CDK4 CDKN2A GSTM1 HRAS TGFBR2
14 lung cancer 29.9 CCND1 CDK4 CDKN2A DLEC1 FHIT GSTM1
15 pancreas adenocarcinoma 29.6 CDKN2A HRAS TP53
16 nasopharyngeal carcinoma 29.6 CCND1 CDK4 CDKN2A GSTM1 HRAS TGFBR2
17 cervical cancer 29.6 CDKN2A FHIT HRAS TP53 VEGFC
18 squamous cell carcinoma, head and neck 29.5 CCND1 CDK4 CDKN2A FHIT GSTM1 HRAS
19 colorectal cancer 28.8 CCND1 CDK4 CDKN2A DCC FHIT GSTM1
20 tylosis with esophageal cancer 12.5
21 carcinoma of esophagus, salivary gland type 12.0
22 undifferentiated carcinoma of esophagus 12.0
23 esophageal cancer, childhood 12.0
24 esophagitis 11.1
25 esophagus squamous cell carcinoma 11.1
26 esophagus verrucous carcinoma 10.9
27 esophageal basaloid squamous cell carcinoma 10.9
28 esophagus small cell carcinoma 10.9
29 squamous cell carcinoma of the larynx 10.9 CDKN2A GSTM1 TP53
30 pharynx cancer 10.9 CCND1 CDKN2A GSTM1 TP53
31 balanitis xerotica obliterans 10.9 CCND1 CDKN2A TP53
32 esophagus sarcoma 10.9
33 lynch syndrome 10.9 CCND1 CDKN2A GSTM1 TP53
34 pre-malignant neoplasm 10.9 CCND1 CDKN2A TP53
35 retinal cancer 10.9 CCND1 CDK4 CDKN2A TP53
36 sensory system cancer 10.9 CCND1 CDK4 CDKN2A TP53
37 ocular cancer 10.9 CCND1 CDK4 CDKN2A TP53
38 nervous system cancer 10.9 CCND1 CDK4 CDKN2A TP53
39 ischemic fasciitis 10.8 CCND1 CDK4 CDKN2A
40 brain stem astrocytic neoplasm 10.8 CDKN2A TP53
41 breast papillomatosis 10.8 CCND1 CDKN2A
42 dedifferentiated liposarcoma 10.8 CDK4 CDKN2A TP53
43 infiltrating angiolipoma 10.8 CDK4 CDKN2A VEGFC
44 small cell sarcoma 10.8 CDK4 CDKN2A TP53
45 mantle cell lymphoma 10.8 CCND1 CDK4 CDKN2A TP53
46 tongue squamous cell carcinoma 10.8 CDKN2A TP53 VEGFC
47 megaesophagus 10.8 CDKN2A FHIT TP53
48 oral cancer 10.8 CCND1 CDKN2A FHIT GSTM1 TP53
49 larynx cancer 10.8 CCND1 CDKN2A FHIT GSTM1 TP53
50 squamous cell carcinoma of the oropharynx 10.8 CDKN2A TP53

Comorbidity relations with Esophageal Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Deficiency Anemia
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Heart Disease
Neutropenia Protein-Energy Malnutrition
Swallowing Disorders

Graphical network of the top 20 diseases related to Esophageal Cancer:



Diseases related to Esophageal Cancer

Symptoms & Phenotypes for Esophageal Cancer

Symptoms via clinical synopsis from OMIM:

53
Oncology:
esophageal cancer

Misc:
frequent loss of heterozygosity of apc and/or mcc genes


Clinical features from OMIM:

133239

Human phenotypes related to Esophageal Cancer:

55 31 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chest pain 55 31 frequent (33%) Frequent (79-30%) HP:0100749
2 abnormality of the voice 55 31 frequent (33%) Frequent (79-30%) HP:0001608
3 cough 55 31 frequent (33%) Frequent (79-30%) HP:0012735
4 lymphadenopathy 55 31 frequent (33%) Occasional (29-5%) HP:0002716
5 nausea and vomiting 55 Frequent (79-30%)
6 obesity 31 occasional (7.5%) HP:0001513
7 dysphagia 31 hallmark (90%) HP:0002015
8 recurrent singultus 31 frequent (33%) HP:0100247
9 gastroesophageal reflux 31 frequent (33%) HP:0002020
10 feeding difficulties in infancy 55 Very frequent (99-80%)
11 weight loss 31 hallmark (90%) HP:0001824
12 abnormality of the neck 31 frequent (33%) HP:0000464
13 squamous cell carcinoma 31 HP:0002860
14 abnormality of the intestine 31 occasional (7.5%) HP:0002242
15 clinodactyly of the 5th toe 55 Very frequent (99-80%)
16 esophageal carcinoma 55 Very frequent (99-80%)
17 barrett esophagus 31 occasional (7.5%) HP:0100580

UMLS symptoms related to Esophageal Cancer:


dyspepsia, abdominal pain, gastrointestinal gas, equilibration disorder, vertigo/dizziness, sore throat, tinnitus, snoring, nausea and vomiting, icterus, heartburn, diarrhea, coughing, constipation

MGI Mouse Phenotypes related to Esophageal Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.17 CDKN2A ALDH2 DCC CCND1 FHIT CDK4
2 endocrine/exocrine gland MP:0005379 10.16 ALDH2 CCND1 CDK4 HRAS CDKN2A TGFBR2
3 digestive/alimentary MP:0005381 10.08 DCC CCND1 FHIT CDK4 HRAS CDKN2A
4 neoplasm MP:0002006 10.06 DCC CCND1 FHIT CDK4 HRAS LZTS1
5 integument MP:0010771 10.01 CDKN2A ALDH2 CCND1 FHIT HRAS CDK4
6 nervous system MP:0003631 10 CDKN2A ALDH2 DCC CCND1 HRAS CDK4
7 liver/biliary system MP:0005370 9.91 CDKN2A ALDH2 CDK4 RHBDF2 TGFBR2 TP53
8 pigmentation MP:0001186 9.63 DCC CDK4 RHBDF2 CDKN2A ALDH2 TP53
9 reproductive system MP:0005389 9.61 CDKN2A ALDH2 CCND1 DLEC1 CDK4 TMPRSS11A
10 vision/eye MP:0005391 9.23 CDKN2A ALDH2 DCC CCND1 CDK4 TGFBR2

Drugs & Therapeutics for Esophageal Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Photodynamic Therapy (& Photofrin) 17 PORFIMER SODIUM Sanofi-aventis January, 1996
2
Photofrin 17 PORFIMER SODIUM QLT January 1998

Drugs for Esophageal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 492)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
5
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7 Racepinephrine Approved Phase 4,Phase 2 329-65-7
8
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
9
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 15663-27-1 2767 441203 84093
10
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
11
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
12
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
13
Levoleucovorin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 68538-85-2
14
Dobutamine Approved Phase 4 34368-04-2 36811
15
Norepinephrine Approved Phase 4 51-41-2 439260
16
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
17
Phenylephrine Approved Phase 4 59-42-7 6041
18
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
19
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
20
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
21
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
22
Nicotine Approved Phase 4 54-11-5 89594 942
23
Iron Approved Phase 4,Phase 1 7439-89-6 23925
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
28
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
29
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
30 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
31 Anticholesteremic Agents Phase 4
32 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
34 Hypolipidemic Agents Phase 4,Phase 1
35 Lipid Regulating Agents Phase 4,Phase 1
36 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 Epinephryl borate Phase 4,Phase 2
38 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
42 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
43 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Early Phase 1
44 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
46 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
49 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2
50 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1248)

# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
3 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
4 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
5 Postoperative Pain Management After Minimally Invasive Esophagectomy Unknown status NCT02042313 Phase 4
6 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
7 Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer Completed NCT00911092 Phase 4 Chemotherapy (Fluorouracil and Cisplatin)
8 INEC Study: Immuno-modulating Enteral Nutrition in Cancer Completed NCT00333099 Phase 4
9 Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection Completed NCT01416077 Phase 4
10 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
11 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Completed NCT00754468 Phase 4
12 Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy Completed NCT02320734 Phase 4 Rocuronium
13 The Effects of Dexmedetomidine on Inflammatory Mediators After One Lung Ventilation During Video-assisted Thoracoscopic Surgery Completed NCT02439905 Phase 4 Dexmedetomidine;Placebo control
14 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
15 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
16 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
17 trūFreeze® Palliative Esophageal Cancer Recruiting NCT03243734 Phase 4
18 Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX Recruiting NCT02609425 Phase 4
19 Radiofrequency in the Treatment of Barrett's Oesophagus Recruiting NCT02558504 Phase 4
20 Iron Replacement in Oesophagogastric Neoplasia Recruiting NCT01927328 Phase 4 Iron isomaltoside 1000
21 Barretts oEsophageal Resection With Steroid Therapy Trial Recruiting NCT02004782 Phase 4 Prednisolone
22 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
23 Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma Not yet recruiting NCT03413436 Phase 4 Lobaplatin;Cisplatin
24 The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I Not yet recruiting NCT02845479 Phase 4
25 Endoscopy Screening for Esophageal Cancer Terminated NCT00927446 Phase 4
26 Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer Unknown status NCT02355249 Phase 3
27 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
28 a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent Unknown status NCT01054274 Phase 3
29 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
30 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
31 Comparable Study of Different Radiation Dose in Esophageal Carcinoma Unknown status NCT01937208 Phase 3 concurrent chemotherapy with radiation
32 Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer Unknown status NCT00686114 Phase 3 Paclitaxel;Cisplatin;Tarceva
33 Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma Unknown status NCT01034683 Phase 3 lobaplatin , 5-FU ,leucovorin
34 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
35 Esophagectomy: Sweet Versus Ivor-Lewis Unknown status NCT01047111 Phase 3
36 Esophagectomy Associated Respiratory Complications: Ivor-Lewis Versus Sweet Approaches Unknown status NCT01053182 Phase 3
37 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
38 Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy Unknown status NCT01242124 Phase 2, Phase 3
39 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
40 Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial Unknown status NCT00193817 Phase 3
41 The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy Unknown status NCT01361750 Phase 3
42 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
43 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer Unknown status NCT01786278 Phase 2, Phase 3
44 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
45 Early Oral Feeding Following Thoracolaparoscopic Oesophagectomy in Patients With Esophageal Cancer Completed NCT01998230 Phase 3
46 Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery Completed NCT00416858 Phase 3 cisplatin;fluorouracil
47 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
48 A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer Completed NCT01249352 Phase 2, Phase 3 Nimotuzumab;Cisplatin;Fluorouracil
49 Surgery or Chemoradiation for Esophageal Cancer Completed NCT01032967 Phase 3
50 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3

Search NIH Clinical Center for Esophageal Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Esophageal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Esophageal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Esophageal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: esophageal neoplasms

Genetic Tests for Esophageal Cancer

Genetic tests related to Esophageal Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Esophagus 28
2 Esophageal Neoplasm 28

Anatomical Context for Esophageal Cancer

MalaCards organs/tissues related to Esophageal Cancer:

38
Lung, Lymph Node, Testes, T Cells, Liver, Bone, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Esophageal Cancer:

18
The Esophagus

Publications for Esophageal Cancer

Articles related to Esophageal Cancer:

(show top 50) (show all 1633)
# Title Authors Year
1
Early diagnostic potential of<i>APC</i>hypermethylation in esophageal cancer. ( 29440928 )
2018
2
Salvage Surgery for Esophageal Cancer: How to Improve Outcomes? ( 29417405 )
2018
3
Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis. ( 29428700 )
2018
4
Minimally invasive esophagectomy may contribute to long-term respiratory function after esophagectomy for esophageal cancer. ( 29444214 )
2018
5
Role of ALDH1 in the prognosis of esophageal cancer and its relationship with tumor microenvironment. ( 28888039 )
2018
6
Neoadjuvant Treatments for Locally Advanced, Resectable Esophageal Cancer: A Network Meta-Analysis. ( 29441562 )
2018
7
The ability of silver(I) thiocyanate 4-methoxyphenyl phosphine to induce apoptotic cell death in esophageal cancer cells is correlated to mitochondrial perturbations. ( 29430579 )
2018
8
Hot Tea and Esophageal Cancer. ( 29404600 )
2018
9
Efficacy comparison of transcervical video-assisted mediastinoscopic lymphadenectomy combined with left transthoracic esophagectomy versus right transthoracic esophagectomy for esophageal cancer treatment. ( 29426329 )
2018
10
SLC52A3 expression is activated by NF-I_B p65/Rel-B and serves as a prognostic biomarker in esophageal cancer. ( 29428966 )
2018
11
Outcomes of abdominal esophageal cancer patients who were treated with esophagectomy. ( 29435289 )
2018
12
Transgastric Endoscopic Submucosal Dissection of Esophageal Cancer with Cervical Stricture. ( 29420854 )
2018
13
Role of<i>MLH1</i>methylation in esophageal cancer carcinogenesis and its clinical significance. ( 29440913 )
2018
14
Cervicothoracoscopic Approach for Esophageal Cancer in a Patient with Right-Sided Aortic Arch. ( 29411200 )
2018
15
Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis. ( 29435296 )
2018
16
Esophageal cancer male to female incidence ratios in Africa: A systematic review and meta-analysis of geographic, time and age trends. ( 29414631 )
2018
17
Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study. ( 29433514 )
2018
18
Diagnosing conduit leak after esophagectomy for esophageal cancer by computed tomography leak protocol and standard esophagram: Is old school still the best? ( 29414520 )
2018
19
The effect of curcumin on cell adhesion of human esophageal cancer cell. ( 29424917 )
2018
20
Detection of HPV16 in Esophageal Cancer in a High-Incidence Region of Malawi. ( 29439548 )
2018
21
Nano Leta897b sensitization of eliminating esophageal cancer stema89like cells is dependent on blockade of Wnt activation of symmetric division. ( 28902370 )
2017
22
Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. ( 29248170 )
2017
23
PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy. ( 28314315 )
2017
24
Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure. ( 28916906 )
2017
25
Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening. ( 28487611 )
2017
26
PIM1 gene silencing inhibits proliferation and promotes apoptosis of human esophageal cancer cell line Eca-109. ( 27983525 )
2017
27
SATB1 plays an oncogenic role in esophageal cancer by up-regulation of FN1 and PDGFRB. ( 28147311 )
2017
28
Quality of Life after Open or Minimally Invasive Esophagectomy in Patients With Esophageal Cancer-A Systematic Review. ( 28939239 )
2017
29
Transcatheter arterial embolization for intercostal arterio-esophageal fistula in esophageal cancer. ( 28510809 )
2017
30
A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer. ( 28498434 )
2017
31
p16 gene silencing along with p53 single-nucleotide polymorphism and risk of esophageal cancer in Northeast India. ( 28459370 )
2017
32
Discrepancy Between Clinical and Pathologic Nodal Status of Esophageal Cancer and Impact on Prognosis and Therapeutic Strategy. ( 28948524 )
2017
33
Optimal Therapy in Locally Advanced Esophageal Cancer: a National Cancer Database Analysis. ( 28940160 )
2017
34
Surgical treatment for esophageal cancer: Are the questions finished or are the surgeons who are finished by the questions? ( 28918965 )
2017
35
Constrictive Pericarditis 5 Months after Radiation Therapy in a 62-Year-Old Woman with Esophageal Cancer. ( 29276442 )
2017
36
Chemoradiotherapy for esophageal cancer before or after surgery: It is not just a matter of time. ( 28527619 )
2017
37
Genetic polymorphisms in TERT are associated with increased risk of esophageal cancer. ( 28060765 )
2017
38
LncRNA Snhg1, a non-degradable sponge for miR-338, promotes expression of proto-oncogene CST3 in primary esophageal cancer cells. ( 28423738 )
2017
39
The effects of air pollution on mortality and clinicopathological features of esophageal cancer. ( 28938579 )
2017
40
LUGOL'S IODINE CHROMOENDOSCOPY VERSUS NARROW BAND IMAGE ENHANCED ENDOSCOPY FOR THE DETECTION OF ESOPHAGEAL CANCER IN PATIENTS WITH STENOSIS SECONDARY TO CAUSTIC/CORROSIVE AGENT INGESTION. ( 28492712 )
2017
41
Azidothymidine inhibits cell growth and telomerase activity and induces DNA damage in human esophageal cancer. ( 28487971 )
2017
42
TM4SF1 promotes the self-renewal of esophageal cancer stem-like cells and is regulated by miR-141. ( 27974706 )
2017
43
Metabolic Perturbation and Potential Markers in Patients with Esophageal Cancer. ( 28512469 )
2017
44
UBE2L6/UBCH8 and ISG15 attenuate autophagy in esophageal cancer cells. ( 28186990 )
2017
45
Minimally invasive Ivor-Lewis esophagectomy for esophageal cancer with right aortic arch. ( 28280627 )
2017
46
Protective Effect of Dietary Calcium Intake on Esophageal Cancer Risk: A Meta-Analysis of Observational Studies. ( 28524093 )
2017
47
Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study. ( 28422774 )
2017
48
Video-assisted thoracic surgery and jejunal reconstruction in a case of situs inversus totalis with esophageal cancer. ( 28681978 )
2017
49
Statin use after esophageal cancer diagnosis and survival: A population based cohort study. ( 28486205 )
2017
50
PLCE1 Promotes Esophageal Cancer Cell Progression by Maintaining the Transcriptional Activity of Snail. ( 28147304 )
2017

Variations for Esophageal Cancer

UniProtKB/Swiss-Prot genetic disease variations for Esophageal Cancer:

71
# Symbol AA change Variation ID SNP ID
1 TGFBR2 p.Glu526Gln VAR_015816 rs121918714

ClinVar genetic disease variations for Esophageal Cancer:

6 (show top 50) (show all 62)
# Gene Variation Type Significance SNP ID Assembly Location
1 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
2 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
5 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
6 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
9 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
10 TP53 NM_000546.5(TP53): c.524G> A (p.Arg175His) single nucleotide variant Pathogenic/Likely pathogenic rs28934578 GRCh37 Chromosome 17, 7578406: 7578406
11 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
12 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
13 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
14 TGFBR2 NM_003242.5(TGFBR2): c.1576G> C (p.Glu526Gln) single nucleotide variant Pathogenic rs121918714 GRCh37 Chromosome 3, 30732963: 30732963
15 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
17 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
18 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
19 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
20 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
22 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
23 DCC NM_005215.3(DCC): c.503T> C (p.Met168Thr) single nucleotide variant Pathogenic rs121912967 GRCh37 Chromosome 18, 50432504: 50432504
24 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
25 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
26 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
27 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
28 SMAD4 NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
29 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic/Likely pathogenic rs377767347 GRCh37 Chromosome 18, 48591919: 48591919
30 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
31 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
32 EGFR NM_005228.4(EGFR): c.2303G> T (p.Ser768Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913465 GRCh37 Chromosome 7, 55249005: 55249005
33 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
34 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
35 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
36 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
37 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
38 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
39 LZTS1 NM_021020.3(LZTS1): c.85T> C (p.Ser29Pro) single nucleotide variant Pathogenic rs28937897 GRCh37 Chromosome 8, 20112608: 20112608
40 LZTS1 NM_021020.3(LZTS1): c.355A> G (p.Lys119Glu) single nucleotide variant Pathogenic rs119473032 GRCh37 Chromosome 8, 20111087: 20111087
41 WWOX NM_016373.3(WWOX): c.872T> C (p.Leu291Pro) single nucleotide variant Pathogenic rs119487098 GRCh37 Chromosome 16, 78466465: 78466465
42 RNF6 NM_005977.3(RNF6): c.305G> A (p.Arg102Lys) single nucleotide variant Pathogenic rs121434522 GRCh37 Chromosome 13, 26789714: 26789714
43 RNF6 NM_005977.3(RNF6): c.724G> A (p.Ala242Thr) single nucleotide variant Pathogenic rs121434523 GRCh37 Chromosome 13, 26789295: 26789295
44 RNF6 NM_005977.3(RNF6): c.731G> A (p.Gly244Asp) single nucleotide variant Pathogenic rs121434524 GRCh37 Chromosome 13, 26789288: 26789288
45 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
46 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
47 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
48 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic/Likely pathogenic rs876659802 GRCh37 Chromosome 17, 7577105: 7577105
49 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
50 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211

Cosmic variations for Esophageal Cancer:

9 (show top 50) (show all 7677)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5049514 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.838+2T>A p.? 21
2 COSM2765083 ZNF831 oesophagus,NS,carcinoma,squamous cell carcinoma c.605T>C p.L202P 21
3 COSM5046772 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.80G>C p.C27S 21
4 COSM5047907 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.777C>A p.Y259* 21
5 COSM5047812 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.668C>G p.S223* 21
6 COSM5048967 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.768C>G p.Y256* 21
7 COSM4834899 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.170C>G p.S57* 21
8 COSM5046823 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.37C>A p.H13N 21
9 COSM5047811 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.938C>G p.S313C 21
10 COSM2158206 ZNF365 oesophagus,NS,carcinoma,squamous cell carcinoma c.712G>A p.E238K 21
11 COSM5047556 ZNF230 oesophagus,NS,carcinoma,squamous cell carcinoma c.87G>C p.Q29H 21
12 COSM5047304 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1162C>T p.R388W 21
13 COSM5049372 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.71A>T p.E24V 21
14 COSM5048093 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.9060G>T p.L3020F 21
15 COSM5048642 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.439G>T p.E147* 21
16 COSM4546868 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.4099G>A p.D1367N 21
17 COSM5048796 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.2120C>G p.S707C 21
18 COSM5048233 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6266C>A p.P2089H 21
19 COSM2876375 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.8374G>A p.G2792R 21
20 COSM389658 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6845G>A p.R2282Q 21
21 COSM751681 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.9517C>T p.P3173S 21
22 COSM5047474 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.10574C>T p.S3525F 21
23 COSM5049692 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.3497C>T p.P1166L 21
24 COSM5048958 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.4132C>T p.Q1378* 21
25 COSM5049693 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.3496C>T p.P1166S 21
26 COSM3276999 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.359G>A p.G120E 21
27 COSM5049149 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.4628G>T p.R1543L 21
28 COSM127037 ZFAT oesophagus,NS,carcinoma,squamous cell carcinoma c.143C>G p.S48* 21
29 COSM5048211 ZFAT oesophagus,NS,carcinoma,squamous cell carcinoma c.2249G>A p.R750H 21
30 COSM5047133 ZC3H7B oesophagus,NS,carcinoma,squamous cell carcinoma c.476T>A p.L159Q 21
31 COSM5047865 ZC3H6 oesophagus,NS,carcinoma,squamous cell carcinoma c.637T>G p.F213V 21
32 COSM2250480 ZC3H14 oesophagus,NS,carcinoma,squamous cell carcinoma c.1793T>A p.L598* 21
33 COSM3481930 ZC3H11A oesophagus,NS,carcinoma,squamous cell carcinoma c.800C>T p.S267F 21
34 COSM5049679 YME1L1 oesophagus,NS,carcinoma,squamous cell carcinoma c.863-2A>G p.? 21
35 COSM2134440 YME1L1 oesophagus,NS,carcinoma,squamous cell carcinoma c.43C>T p.P15S 21
36 COSM5046790 XPO5 oesophagus,NS,carcinoma,squamous cell carcinoma c.2092T>C p.Y698H 21
37 COSM5047544 XIRP2 oesophagus,NS,carcinoma,squamous cell carcinoma c.5215G>A p.E1739K 21
38 COSM5047950 XIRP2 oesophagus,NS,carcinoma,squamous cell carcinoma c.4627G>C p.E1543Q 21
39 COSM5047255 WWC3 oesophagus,NS,carcinoma,squamous cell carcinoma c.2836C>T p.R946* 21
40 COSM5047360 WRN oesophagus,NS,carcinoma,squamous cell carcinoma c.1475C>T p.S492F 21
41 COSM5048456 WEE1 oesophagus,NS,carcinoma,squamous cell carcinoma c.1212G>T p.K404N 21
42 COSM5049604 WDR66 oesophagus,NS,carcinoma,squamous cell carcinoma c.1475A>T p.K492M 21
43 COSM5047589 WDR64 oesophagus,NS,carcinoma,squamous cell carcinoma c.94G>C p.E32Q 21
44 COSM5049378 VSIG8 oesophagus,NS,carcinoma,squamous cell carcinoma c.331A>G p.I111V 21
45 COSM3369233 VPS13D oesophagus,NS,carcinoma,squamous cell carcinoma c.8197+1G>A p.? 21
46 COSM5047981 VPS13D oesophagus,NS,carcinoma,squamous cell carcinoma c.12795-1G>A p.? 21
47 COSM5048630 VPS13D oesophagus,NS,carcinoma,squamous cell carcinoma c.12893T>C p.I4298T 21
48 COSM5048194 VPS13D oesophagus,NS,carcinoma,squamous cell carcinoma c.11390G>A p.R3797Q 21
49 COSM5048387 VPS13B oesophagus,NS,carcinoma,squamous cell carcinoma c.5048G>A p.R1683K 21
50 COSM3268302 VPS13B oesophagus,NS,carcinoma,squamous cell carcinoma c.2336C>A p.T779N 21

Copy number variations for Esophageal Cancer from CNVD:

7 (show top 50) (show all 64)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 32702 1 39027237 40780163 Amplification MYCL1 Esophageal cancer
2 35731 1 66691991 71187083 Deletion CTH Esophageal cancer
3 38511 10 10309026 19155158 Deletion Esophageal cancer
4 41416 10 17811791 65388337 Amplification Esophageal cancer
5 43899 10 50393324 70694787 Deletion Esophageal cancer
6 48565 11 100815801 103042620 Amplification BIRC2 Esophageal cancer
7 48566 11 100815801 103042620 Amplification BIRC3 Esophageal cancer
8 48567 11 100815801 103042620 Amplification YAP1 Esophageal cancer
9 55251 11 50256798 61426521 Deletion Esophageal cancer
10 58612 11 68753086 69985447 Amplification CCND1 Esophageal cancer
11 58613 11 68753086 69985447 Amplification CTTN Esophageal cancer
12 58614 11 68753086 69985447 Amplification FGF19 Esophageal cancer
13 58615 11 68753086 69985447 Amplification FGF3 Esophageal cancer
14 58616 11 68753086 69985447 Amplification FGF4 Esophageal cancer
15 58617 11 68753086 69985447 Amplification MYEOV Esophageal cancer
16 58701 11 69200000 70700000 Gain PPFIA1 Esophageal cancer
17 61418 12 1 132078379 Deletion Esophageal cancer
18 79288 13 68772537 113042980 Deletion Esophageal cancer
19 80978 14 1 105311216 Deletion Esophageal cancer
20 83027 14 19100000 23600000 Gain NFATC4 Esophageal cancer
21 84103 14 23600000 31800000 Gain ARHGAP5 Esophageal cancer
22 84107 14 23600000 36900000 Gain PAX9 Esophageal cancer
23 85295 14 42828345 44176016 Deletion Esophageal cancer
24 111151 17 35097918 35138441 Copy number ERBB2 Esophageal cancer
25 119155 18 1 1118244 Amplification TYMS Esophageal cancer
26 119156 18 1 1118244 Amplification YES1 Esophageal cancer
27 121678 18 46081464 51919972 Deletion SMAD4 Esophageal cancer
28 137284 2 141590067 141951947 Deletion LRP1B Esophageal cancer
29 151504 20 22140447 26145930 Amplification PYGB Esophageal cancer
30 157032 21 1 29932926 Deletion Esophageal cancer
31 160899 22 16558724 17937900 Amplification BID Esophageal cancer
32 160900 22 16558724 17937900 Amplification CLDN5 Esophageal cancer
33 161388 22 18577713 20667607 Amplification CRKL Esophageal cancer
34 161389 22 18577713 20667607 Amplification MAPK1 Esophageal cancer
35 163870 22 31889314 32003182 Amplification LARGE Esophageal cancer
36 166067 3 1 199344050 Deletion Esophageal cancer
37 169829 3 14700000 43600000 Loss RAB5A Esophageal cancer
38 171482 3 168801287 168851758 Amplification EVI1 Esophageal cancer
39 171491 3 168867391 169381563 Amplification MDS1 Esophageal cancer
40 173071 3 189400000 193800000 Gain TP63 Esophageal cancer
41 174749 3 32100000 54400000 Loss SCN10A Esophageal cancer
42 175197 3 3800000 87200000 Loss ATXN7 Esophageal cancer
43 175734 3 43600000 51400000 Loss CTDSPL Esophageal cancer
44 177631 3 59735036 61237133 Deletion FHIT Esophageal cancer
45 179189 3 8700000 14700000 Loss RAF1 Esophageal cancer
46 179592 3 95917505 101945216 Amplification MINA Esophageal cancer
47 190878 4 91972774 162358674 Deletion CASP6 Esophageal cancer
48 190879 4 91972774 162358674 Deletion SMAD1 Esophageal cancer
49 191757 5 10051329 11800765 Amplification CTNND2 Esophageal cancer
50 198525 5 25700000 76400000 Loss F2R Esophageal cancer

Expression for Esophageal Cancer

Search GEO for disease gene expression data for Esophageal Cancer.

Pathways for Esophageal Cancer

Pathways related to Esophageal Cancer according to KEGG:

36
# Name Kegg Source Accession
1 MicroRNAs in cancer hsa05206

Pathways related to Esophageal Cancer according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.96 CCND1 CDK4 CDKN2A DCC FHIT HRAS
2
Show member pathways
12.67 CCND1 CDK4 CDKN2A GSTM1 HRAS TGFBR2
3 12.43 CCND1 CDK4 CDKN2A TP53 WWOX
4
Show member pathways
12.39 CCND1 CDK4 CDKN2A HRAS TGFBR2 TP53
5 12.32 CCND1 CDK4 CDKN2A HRAS TGFBR2 TP53
6
Show member pathways
12.3 CCND1 CDK4 CDKN2A TP53
7 12.29 CCND1 CDK4 CDKN2A TP53
8
Show member pathways
12.27 CCND1 CDK4 CDKN2A TP53
9 12.2 CCND1 CDK4 CDKN2A HRAS TP53
10
Show member pathways
12.16 CCND1 CDK4 CDKN2A TGFBR2
11 12.11 CCND1 DCC TGFBR2 TP53
12 12.07 CCND1 CDK4 TGFBR2 TP53
13 12 CCND1 CDK4 CDKN2A DCC GSTM1 HRAS
14 11.99 CCND1 CDK4 CDKN2A TP53
15 11.89 CCND1 CDKN2A HRAS TP53
16 11.85 CCND1 CDK4 CDKN2A HRAS TP53
17 11.84 CCND1 CDK4 CDKN2A HRAS TGFBR2 TP53
18 11.78 CCND1 CDK4 FHIT TP53
19 11.76 CCND1 CDK4 TP53
20 11.76 CCND1 CDK4 HRAS TGFBR2 VEGFC
21 11.66 CDKN2A GSTM1 TP53
22
Show member pathways
11.62 CCND1 CDK4 CDKN2A HRAS TGFBR2 TP53
23 11.52 CCND1 CDK4 CDKN2A HRAS TP53
24 11.51 CDKN2A TP53 VEGFC
25 11.48 CCND1 CDKN2A TP53
26 11.4 CCND1 CDK4 TP53
27 11.23 CCND1 CDK4 TP53
28 11.22 CDK4 CDKN2A TP53

GO Terms for Esophageal Cancer

Biological processes related to Esophageal Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 CCND1 CDK4 HRAS TGFBR2 VEGFC
2 cell cycle GO:0007049 9.91 CCND1 CDK4 CDKN2A LZTS1 TMPRSS11A TP53
3 response to drug GO:0042493 9.77 CCND1 CDK4 TGFBR2 TP53 VEGFC
4 G1/S transition of mitotic cell cycle GO:0000082 9.71 CCND1 CDK4 CDKN2A
5 response to organic substance GO:0010033 9.7 CCND1 CDK4 TGFBR2
6 Ras protein signal transduction GO:0007265 9.63 CDKN2A HRAS TP53
7 animal organ regeneration GO:0031100 9.58 CCND1 CDK4 TGFBR2
8 positive regulation of cell cycle GO:0045787 9.5 CCND1 CDK4 TP53
9 apoptotic process GO:0006915 9.5 CDKN2A DCC FHIT HRAS TGFBR2 TP53
10 replicative senescence GO:0090399 9.49 CDKN2A TP53
11 mitotic G1 DNA damage checkpoint GO:0031571 9.48 CCND1 TP53
12 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.43 FHIT TP53 WWOX
13 cellular senescence GO:0090398 9.33 C2orf40 CDKN2A HRAS
14 negative regulation of cell proliferation GO:0008285 9.17 CDKN2A DEC1 DLEC1 HRAS TGFBR2 TP53

Sources for Esophageal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....